Group One Trading
APLS

Group One Trading’s Apellis Pharmaceuticals APLS Stock Holding History

Group One Trading’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.1M Sell
226,200
-7,700
-3% -$166K 0.02% 897
2025
Q4 		$5.88M Buy
233,900
+54,800
+31% +$1.29M 0.01% 1340
2025
Q3 		$4.05M Buy
179,100
+33,500
+23% +$781K 0.01% 1666
2025
Q2 		$2.52M Sell
145,600
-62,600
-30% -$1.16M 0.01% 1910
2025
Q1 		$4.55M Sell
208,200
-69,100
-25% -$1.91M 0.01% 1144
2024
Q4 		$8.85M Sell
277,300
-64,800
-19% -$1.95M 0.02% 779
2024
Q3 		$9.87M Buy
342,100
+62,500
+22% +$2.31M 0.03% 628
2024
Q2 		$10.7M Buy
279,600
+53,500
+24% +$2.42M 0.04% 411
2024
Q1 		$13.3M Sell
226,100
-139,600
-38% -$8.9M 0.05% 322
2023
Q4 		$21.9M Sell
365,700
-578,700
-61% -$29.4M 0.06% 310
2023
Q3 		$35.9M Buy
944,400
+885,800
+1,512% +$38.9M 0.12% 106
2023
Q2 		$5.34M Sell
58,600
-51,300
-47% -$4.43M 0.02% 913
2023
Q1 		$7.25M Buy
109,900
+8,400
+8% +$485K 0.03% 639
2022
Q4 		$5.25M Buy
101,500
+39,200
+63% +$2.08M 0.01% 1110
2022
Q3 		$4.25M Buy
62,300
+12,800
+26% +$757K 0.01% 1284
2022
Q2 		$2.24M Buy
49,500
+7,200
+17% +$328K ﹤0.01% 1959
2022
Q1 		$2.15M Buy
42,300
+22,200
+110% +$980K ﹤0.01% 2328
2021
Q4 		$950K Sell
20,100
-71,900
-78% -$2.83M ﹤0.01% 3409
2021
Q3 		$3.03M Buy
92,000
+2,900
+3% +$163K ﹤0.01% 2231
2021
Q2 		$5.63M Sell
89,100
-35,300
-28% -$1.82M 0.01% 1577
2021
Q1 		$5.34M Buy
124,400
+40,900
+49% +$1.94M 0.01% 1462
2020
Q4 		$4.78M Buy
83,500
+80,700
+2,882% +$3.41M 0.01% 1310
2020
Q3 		$84K Sell
2,800
-72,900
-96% -$2.18M ﹤0.01% 4309
2020
Q2 		$2.47M Buy
75,700
+1,600
+2% +$51.4K 0.01% 1315
2020
Q1 		$1.99M Buy
74,100
+61,200
+474% +$2.17M 0.02% 1051
2019
Q4 		$395K Buy
+12,900
New +$357K ﹤0.01% 2632

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Group One Trading's APLS Position: Q4 2025 in Review

Group One Trading sold out of Apellis Pharmaceuticals (APLS) in Q4 2025, closing a stake of 14,925 shares — an estimated $350K sold.

Group One Trading first reported a position in APLS in Q3 2019 and held it in 16 quarters. The position peaked at $15.2M in Q4 2023. 278 funds tracked by Wall St. Rank hold APLS as of Q4 2025.

  • Group One Trading reported no remaining Apellis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Group One Trading sold 14,925 Apellis Pharmaceuticals shares in Q4 2025, an estimated $350K.
  • Group One Trading first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 16 quarters.
  • Group One Trading's Apellis Pharmaceuticals position peaked at $15.2M in Q4 2023.
  • 278 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2025.

Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.